NASDAQ · VNRX
Healthcare · Medical - Diagnostics & Research
$0.24
Down-$0.01 (-4.03%)
Updated Oct 7, 2026, 4:46 PM
SID Score
3.2/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · VNRX
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 6, 2026
VNRX closed at $0.24 after 21 trading sessions, down 26.90% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 6, 2026 | $0.233 | $0.2474 | $0.2321 | $0.2429 | 644.26K |
| Oct 5, 2026 | $0.2342 | $0.2429 | $0.2317 | $0.232 | 716.93K |
| Oct 2, 2026 | $0.2412 | $0.2412 | $0.23 | $0.235 | 1.38M |
| Oct 1, 2026 | $0.2521 | $0.2626 | $0.234 | $0.2347 | 8.14M |
| Sep 30, 2026 | $0.2561 | $0.2607 | $0.2467 | $0.258 | 1.44M |
| Sep 29, 2026 | $0.25 | $0.2635 | $0.2485 | $0.2561 | 2.11M |
| Sep 28, 2026 | $0.2532 | $0.2552 | $0.2427 | $0.2529 | 912.63K |
| Sep 25, 2026 | $0.2478 | $0.261 | $0.2306 | $0.259 | 2.89M |
| Sep 24, 2026 | $0.2434 | $0.2515 | $0.2434 | $0.2458 | 893.49K |
| Sep 23, 2026 | $0.256 | $0.26 | $0.2327 | $0.247 | 2.84M |
| Sep 22, 2026 | $0.2629 | $0.2635 | $0.255 | $0.2632 | 1.72M |
| Sep 21, 2026 | $0.2602 | $0.2649 | $0.256 | $0.2649 | 1.86M |
| Sep 18, 2026 | $0.275 | $0.275 | $0.2407 | $0.26 | 4.37M |
| Sep 17, 2026 | $0.29 | $0.2951 | $0.2729 | $0.2849 | 28.23M |
| Sep 16, 2026 | $0.28 | $0.287 | $0.2749 | $0.2749 | 1.44M |
| Sep 15, 2026 | $0.30 | $0.3006 | $0.2825 | $0.2893 | 2.18M |
| Sep 14, 2026 | $0.3139 | $0.3144 | $0.3009 | $0.3121 | 2.36M |
| Sep 11, 2026 | $0.3371 | $0.3401 | $0.3058 | $0.3102 | 1.11M |
| Sep 10, 2026 | $0.348 | $0.348 | $0.3253 | $0.34 | 941.06K |
| Sep 9, 2026 | $0.3321 | $0.3609 | $0.3229 | $0.342 | 2M |
| Sep 8, 2026 | $0.344 | $0.345 | $0.3317 | $0.3323 | 1.31M |
The latest Smart Investors Daily articles mentioning VNRX.
Company
Market Activity
Research & News
VNRX research
Company profile and research snapshot.
VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jun 18, 2026 | Maxim Group | Buy | — |
| Apr 20, 2026 | D. Boral Capital | Hold | — |
| Apr 2, 2026 | HC Wainwright & Co. | Buy | — |
| Mar 31, 2026 | D. Boral Capital | Buy | — |
| Mar 26, 2026 | D. Boral Capital | Buy | — |
No generated briefing is available yet.
Yahoo · Sep 17, 2026
VolitionRx Limited (NYSE AMERICAN: VNRX) (XASE: VNRX) (together with affiliates "Volition"), a multi-national epigenetics company, as part of the Government-funded DETECSEPS Consortium in France, today shares further details about the official launch of the project on the early detection of sepsis.
Yahoo · Sep 17, 2026
VolitionRx Limited (NYSE AMERICAN: VNRX) (XASE: VNRX) (together with affiliates, "Volition"), a multi-national epigenetics company, today announces, as part of the DETECSEPS Consortium, the official launch of the DETECSEPS project on the early detection of sepsis. The Consortium is funded with €6.3 million (~$7.3 million) from the French government.
Benzinga · Sep 17, 2026
French Government-Funded €6.3 million (~$7.3 million) Consortium Selects Volition's Nu.Q® NETs Assay as Sole Biomarker for France's Real World Evaluation of Early Detection of SepsisHENDERSON, Nev., Sept. 17,
Yahoo · Sep 14, 2026
VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces the full pre-payment in cash of the outstanding balance on its senior secured convertible promissory note, dated May 20, 2025, in the original principal amount of $7,500,000 (the "Note"), issued to Lind Global Asset Management XII LLC ("Lind"). Following the pre-payment, all obligations under the Note have been satisfied. The senior secured convertible promissory note, dated January 7, 20
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning VNRX.
